Profiel
Dr. Florian D.
Vogl was previously employed as a Chief Medical Officer by Immutep Ltd., a Chief Medical Officer by Cellestia Biotech AG, and a Head-Clinical Development Europe by Rainier Therapeutics, Inc. He received his doctorate degree from Ludwig-Maximilians-Universität München.
Eerdere bekende functies van Florian Vogl
| Bedrijven | Functie | Einde |
|---|---|---|
Cellestia Biotech AG
Cellestia Biotech AG Pharmaceuticals: MajorHealth Technology Manufactures anti-cancer drugs | Hoofd Techniek/Wetenschap/O&O | 01-05-2023 |
Rainier Therapeutics, Inc.
Rainier Therapeutics, Inc. BiotechnologyHealth Technology Operates as clinical stage biotechnology company developing a targeted biologic for the potential treatment of both early stage and metastatic bladder cancer | Corporate Officer/Principal | 01-12-2019 |
| IMMUTEP LIMITED | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Florian Vogl
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 4 |
|---|---|
Immutep Ltd.
Immutep Ltd. BiotechnologyHealth Technology Engages in the development of anti-cancer therapeutics | Health Technology |
Ludwig-Maximilians-Universität München
Ludwig-Maximilians-Universität München Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Rainier Therapeutics, Inc.
Rainier Therapeutics, Inc. BiotechnologyHealth Technology Operates as clinical stage biotechnology company developing a targeted biologic for the potential treatment of both early stage and metastatic bladder cancer | Health Technology |
Cellestia Biotech AG
Cellestia Biotech AG Pharmaceuticals: MajorHealth Technology Manufactures anti-cancer drugs | Health Technology |
















